nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—prostate cancer	0.181	0.611	CbGaD
Sitaxentan—CYP3A4—prostate cancer	0.115	0.389	CbGaD
Sitaxentan—CYP2C19—Bicalutamide—prostate cancer	0.0367	0.0931	CbGbCtD
Sitaxentan—CYP2C19—Nilutamide—prostate cancer	0.0367	0.0931	CbGbCtD
Sitaxentan—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0338	0.0857	CbGbCtD
Sitaxentan—CYP2C9—Nilutamide—prostate cancer	0.0305	0.0774	CbGbCtD
Sitaxentan—CYP2C9—Bicalutamide—prostate cancer	0.0305	0.0774	CbGbCtD
Sitaxentan—CYP2C19—Flutamide—prostate cancer	0.0304	0.0772	CbGbCtD
Sitaxentan—CYP2C9—Estrone—prostate cancer	0.0183	0.0464	CbGbCtD
Sitaxentan—CYP3A4—Bicalutamide—prostate cancer	0.0177	0.045	CbGbCtD
Sitaxentan—CYP3A4—Estramustine—prostate cancer	0.0165	0.0418	CbGbCtD
Sitaxentan—CYP3A4—Flutamide—prostate cancer	0.0147	0.0373	CbGbCtD
Sitaxentan—CYP3A4—Abiraterone—prostate cancer	0.0147	0.0373	CbGbCtD
Sitaxentan—CYP2C9—Capecitabine—prostate cancer	0.0138	0.0351	CbGbCtD
Sitaxentan—CYP2C19—Estradiol—prostate cancer	0.0126	0.032	CbGbCtD
Sitaxentan—CYP3A4—Cabazitaxel—prostate cancer	0.0109	0.0276	CbGbCtD
Sitaxentan—CYP2C19—Prednisone—prostate cancer	0.0109	0.0275	CbGbCtD
Sitaxentan—CYP3A4—Estrone—prostate cancer	0.0106	0.027	CbGbCtD
Sitaxentan—CYP2C9—Estradiol—prostate cancer	0.0105	0.0266	CbGbCtD
Sitaxentan—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00947	0.024	CbGbCtD
Sitaxentan—CYP3A4—Conjugated Estrogens—prostate cancer	0.00695	0.0176	CbGbCtD
Sitaxentan—CYP3A4—Mitoxantrone—prostate cancer	0.00632	0.016	CbGbCtD
Sitaxentan—CYP3A4—Estradiol—prostate cancer	0.0061	0.0155	CbGbCtD
Sitaxentan—CYP3A4—Prednisone—prostate cancer	0.00525	0.0133	CbGbCtD
Sitaxentan—CYP3A4—Etoposide—prostate cancer	0.00398	0.0101	CbGbCtD
Sitaxentan—CYP3A4—Docetaxel—prostate cancer	0.00365	0.00925	CbGbCtD
Sitaxentan—EDNRB—prostate gland—prostate cancer	0.00322	0.131	CbGeAlD
Sitaxentan—CYP2C19—urine—prostate cancer	0.00316	0.129	CbGeAlD
Sitaxentan—CYP3A4—Doxorubicin—prostate cancer	0.00272	0.0069	CbGbCtD
Sitaxentan—EDNRA—prostate gland—prostate cancer	0.00266	0.109	CbGeAlD
Sitaxentan—CYP2C9—urine—prostate cancer	0.00245	0.1	CbGeAlD
Sitaxentan—EDNRA—seminal vesicle—prostate cancer	0.00225	0.0919	CbGeAlD
Sitaxentan—EDNRB—urethra—prostate cancer	0.00215	0.088	CbGeAlD
Sitaxentan—CYP3A4—urine—prostate cancer	0.00187	0.0764	CbGeAlD
Sitaxentan—EDNRA—urethra—prostate cancer	0.00178	0.0728	CbGeAlD
Sitaxentan—EDNRB—testis—prostate cancer	0.00142	0.0579	CbGeAlD
Sitaxentan—EDNRA—testis—prostate cancer	0.00117	0.0479	CbGeAlD
Sitaxentan—EDNRB—lymph node—prostate cancer	0.00103	0.042	CbGeAlD
Sitaxentan—EDNRA—lymph node—prostate cancer	0.000849	0.0347	CbGeAlD
Sitaxentan—CYP3A4—renal system—prostate cancer	0.000457	0.0187	CbGeAlD
Sitaxentan—Confusional state—Docetaxel—prostate cancer	2.63e-05	0.000138	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	2.62e-05	0.000137	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Doxorubicin—prostate cancer	2.61e-05	0.000137	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Epirubicin—prostate cancer	2.61e-05	0.000136	CcSEcCtD
Sitaxentan—Oedema—Docetaxel—prostate cancer	2.61e-05	0.000136	CcSEcCtD
Sitaxentan—Discomfort—Capecitabine—prostate cancer	2.6e-05	0.000136	CcSEcCtD
Sitaxentan—Epistaxis—Epirubicin—prostate cancer	2.6e-05	0.000136	CcSEcCtD
Sitaxentan—Infection—Docetaxel—prostate cancer	2.59e-05	0.000136	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—prostate cancer	2.59e-05	0.000135	CcSEcCtD
Sitaxentan—Sinusitis—Epirubicin—prostate cancer	2.59e-05	0.000135	CcSEcCtD
Sitaxentan—Feeling abnormal—Etoposide—prostate cancer	2.59e-05	0.000135	CcSEcCtD
Sitaxentan—Hyperglycaemia—Doxorubicin—prostate cancer	2.58e-05	0.000135	CcSEcCtD
Sitaxentan—Diarrhoea—Mitoxantrone—prostate cancer	2.58e-05	0.000135	CcSEcCtD
Sitaxentan—Dry mouth—Capecitabine—prostate cancer	2.58e-05	0.000135	CcSEcCtD
Sitaxentan—Vomiting—Estradiol—prostate cancer	2.57e-05	0.000135	CcSEcCtD
Sitaxentan—Nervous system disorder—Docetaxel—prostate cancer	2.56e-05	0.000134	CcSEcCtD
Sitaxentan—Ill-defined disorder—Prednisone—prostate cancer	2.56e-05	0.000134	CcSEcCtD
Sitaxentan—Thrombocytopenia—Docetaxel—prostate cancer	2.55e-05	0.000134	CcSEcCtD
Sitaxentan—Rash—Estradiol—prostate cancer	2.55e-05	0.000134	CcSEcCtD
Sitaxentan—Infestation NOS—Doxorubicin—prostate cancer	2.55e-05	0.000133	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—prostate cancer	2.55e-05	0.000133	CcSEcCtD
Sitaxentan—Dermatitis—Estradiol—prostate cancer	2.55e-05	0.000133	CcSEcCtD
Sitaxentan—Anaemia—Prednisone—prostate cancer	2.55e-05	0.000133	CcSEcCtD
Sitaxentan—Confusional state—Capecitabine—prostate cancer	2.55e-05	0.000133	CcSEcCtD
Sitaxentan—Tachycardia—Docetaxel—prostate cancer	2.55e-05	0.000133	CcSEcCtD
Sitaxentan—Headache—Estradiol—prostate cancer	2.54e-05	0.000133	CcSEcCtD
Sitaxentan—Skin disorder—Docetaxel—prostate cancer	2.53e-05	0.000132	CcSEcCtD
Sitaxentan—Agitation—Prednisone—prostate cancer	2.53e-05	0.000132	CcSEcCtD
Sitaxentan—Oedema—Capecitabine—prostate cancer	2.53e-05	0.000132	CcSEcCtD
Sitaxentan—Bradycardia—Epirubicin—prostate cancer	2.52e-05	0.000132	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—prostate cancer	2.51e-05	0.000131	CcSEcCtD
Sitaxentan—Infection—Capecitabine—prostate cancer	2.51e-05	0.000131	CcSEcCtD
Sitaxentan—Urticaria—Etoposide—prostate cancer	2.49e-05	0.00013	CcSEcCtD
Sitaxentan—Haemoglobin—Epirubicin—prostate cancer	2.49e-05	0.00013	CcSEcCtD
Sitaxentan—Stomatitis—Doxorubicin—prostate cancer	2.49e-05	0.00013	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—prostate cancer	2.49e-05	0.00013	CcSEcCtD
Sitaxentan—Anorexia—Docetaxel—prostate cancer	2.49e-05	0.00013	CcSEcCtD
Sitaxentan—Malaise—Prednisone—prostate cancer	2.49e-05	0.00013	CcSEcCtD
Sitaxentan—Rhinitis—Epirubicin—prostate cancer	2.48e-05	0.00013	CcSEcCtD
Sitaxentan—Body temperature increased—Etoposide—prostate cancer	2.48e-05	0.00013	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—prostate cancer	2.48e-05	0.00013	CcSEcCtD
Sitaxentan—Nervous system disorder—Capecitabine—prostate cancer	2.48e-05	0.00013	CcSEcCtD
Sitaxentan—Vertigo—Prednisone—prostate cancer	2.48e-05	0.00013	CcSEcCtD
Sitaxentan—Haemorrhage—Epirubicin—prostate cancer	2.48e-05	0.00013	CcSEcCtD
Sitaxentan—Hepatitis—Epirubicin—prostate cancer	2.48e-05	0.00013	CcSEcCtD
Sitaxentan—Thrombocytopenia—Capecitabine—prostate cancer	2.47e-05	0.000129	CcSEcCtD
Sitaxentan—Tachycardia—Capecitabine—prostate cancer	2.46e-05	0.000129	CcSEcCtD
Sitaxentan—Skin disorder—Capecitabine—prostate cancer	2.45e-05	0.000128	CcSEcCtD
Sitaxentan—Urinary tract disorder—Epirubicin—prostate cancer	2.45e-05	0.000128	CcSEcCtD
Sitaxentan—Oedema peripheral—Epirubicin—prostate cancer	2.44e-05	0.000128	CcSEcCtD
Sitaxentan—Hypotension—Docetaxel—prostate cancer	2.44e-05	0.000127	CcSEcCtD
Sitaxentan—Haematuria—Doxorubicin—prostate cancer	2.43e-05	0.000127	CcSEcCtD
Sitaxentan—Urethral disorder—Epirubicin—prostate cancer	2.43e-05	0.000127	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—prostate cancer	2.41e-05	0.000126	CcSEcCtD
Sitaxentan—Epistaxis—Doxorubicin—prostate cancer	2.41e-05	0.000126	CcSEcCtD
Sitaxentan—Anorexia—Capecitabine—prostate cancer	2.41e-05	0.000126	CcSEcCtD
Sitaxentan—Nausea—Estradiol—prostate cancer	2.41e-05	0.000126	CcSEcCtD
Sitaxentan—Vomiting—Mitoxantrone—prostate cancer	2.4e-05	0.000125	CcSEcCtD
Sitaxentan—Sinusitis—Doxorubicin—prostate cancer	2.39e-05	0.000125	CcSEcCtD
Sitaxentan—Visual impairment—Epirubicin—prostate cancer	2.39e-05	0.000125	CcSEcCtD
Sitaxentan—Rash—Mitoxantrone—prostate cancer	2.38e-05	0.000124	CcSEcCtD
Sitaxentan—Dermatitis—Mitoxantrone—prostate cancer	2.38e-05	0.000124	CcSEcCtD
Sitaxentan—Headache—Mitoxantrone—prostate cancer	2.36e-05	0.000124	CcSEcCtD
Sitaxentan—Hypotension—Capecitabine—prostate cancer	2.36e-05	0.000123	CcSEcCtD
Sitaxentan—Insomnia—Docetaxel—prostate cancer	2.36e-05	0.000123	CcSEcCtD
Sitaxentan—Bradycardia—Doxorubicin—prostate cancer	2.33e-05	0.000122	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.33e-05	0.000122	CcSEcCtD
Sitaxentan—Somnolence—Docetaxel—prostate cancer	2.32e-05	0.000121	CcSEcCtD
Sitaxentan—Discomfort—Prednisone—prostate cancer	2.32e-05	0.000121	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—prostate cancer	2.31e-05	0.000121	CcSEcCtD
Sitaxentan—Hypersensitivity—Etoposide—prostate cancer	2.31e-05	0.000121	CcSEcCtD
Sitaxentan—Tinnitus—Epirubicin—prostate cancer	2.31e-05	0.000121	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—prostate cancer	2.3e-05	0.00012	CcSEcCtD
Sitaxentan—Cardiac disorder—Epirubicin—prostate cancer	2.3e-05	0.00012	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—prostate cancer	2.3e-05	0.00012	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—prostate cancer	2.3e-05	0.00012	CcSEcCtD
Sitaxentan—Dyspepsia—Docetaxel—prostate cancer	2.3e-05	0.00012	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—prostate cancer	2.29e-05	0.00012	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—prostate cancer	2.29e-05	0.00012	CcSEcCtD
Sitaxentan—Insomnia—Capecitabine—prostate cancer	2.28e-05	0.000119	CcSEcCtD
Sitaxentan—Decreased appetite—Docetaxel—prostate cancer	2.27e-05	0.000119	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—prostate cancer	2.26e-05	0.000118	CcSEcCtD
Sitaxentan—Oedema peripheral—Doxorubicin—prostate cancer	2.26e-05	0.000118	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Docetaxel—prostate cancer	2.25e-05	0.000118	CcSEcCtD
Sitaxentan—Asthenia—Etoposide—prostate cancer	2.25e-05	0.000118	CcSEcCtD
Sitaxentan—Oedema—Prednisone—prostate cancer	2.25e-05	0.000118	CcSEcCtD
Sitaxentan—Fatigue—Docetaxel—prostate cancer	2.25e-05	0.000118	CcSEcCtD
Sitaxentan—Angiopathy—Epirubicin—prostate cancer	2.25e-05	0.000117	CcSEcCtD
Sitaxentan—Urethral disorder—Doxorubicin—prostate cancer	2.25e-05	0.000117	CcSEcCtD
Sitaxentan—Nausea—Mitoxantrone—prostate cancer	2.24e-05	0.000117	CcSEcCtD
Sitaxentan—Immune system disorder—Epirubicin—prostate cancer	2.24e-05	0.000117	CcSEcCtD
Sitaxentan—Infection—Prednisone—prostate cancer	2.23e-05	0.000117	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—prostate cancer	2.23e-05	0.000117	CcSEcCtD
Sitaxentan—Constipation—Docetaxel—prostate cancer	2.23e-05	0.000117	CcSEcCtD
Sitaxentan—Pain—Docetaxel—prostate cancer	2.23e-05	0.000117	CcSEcCtD
Sitaxentan—Dyspepsia—Capecitabine—prostate cancer	2.22e-05	0.000116	CcSEcCtD
Sitaxentan—Visual impairment—Doxorubicin—prostate cancer	2.21e-05	0.000115	CcSEcCtD
Sitaxentan—Nervous system disorder—Prednisone—prostate cancer	2.21e-05	0.000115	CcSEcCtD
Sitaxentan—Tachycardia—Prednisone—prostate cancer	2.2e-05	0.000115	CcSEcCtD
Sitaxentan—Decreased appetite—Capecitabine—prostate cancer	2.2e-05	0.000115	CcSEcCtD
Sitaxentan—Alopecia—Epirubicin—prostate cancer	2.19e-05	0.000114	CcSEcCtD
Sitaxentan—Skin disorder—Prednisone—prostate cancer	2.19e-05	0.000114	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Capecitabine—prostate cancer	2.18e-05	0.000114	CcSEcCtD
Sitaxentan—Fatigue—Capecitabine—prostate cancer	2.18e-05	0.000114	CcSEcCtD
Sitaxentan—Mental disorder—Epirubicin—prostate cancer	2.17e-05	0.000113	CcSEcCtD
Sitaxentan—Pain—Capecitabine—prostate cancer	2.16e-05	0.000113	CcSEcCtD
Sitaxentan—Constipation—Capecitabine—prostate cancer	2.16e-05	0.000113	CcSEcCtD
Sitaxentan—Malnutrition—Epirubicin—prostate cancer	2.16e-05	0.000113	CcSEcCtD
Sitaxentan—Feeling abnormal—Docetaxel—prostate cancer	2.15e-05	0.000112	CcSEcCtD
Sitaxentan—Diarrhoea—Etoposide—prostate cancer	2.15e-05	0.000112	CcSEcCtD
Sitaxentan—Anorexia—Prednisone—prostate cancer	2.14e-05	0.000112	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—prostate cancer	2.14e-05	0.000112	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—prostate cancer	2.14e-05	0.000112	CcSEcCtD
Sitaxentan—Flushing—Doxorubicin—prostate cancer	2.13e-05	0.000111	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—prostate cancer	2.13e-05	0.000111	CcSEcCtD
Sitaxentan—Tension—Epirubicin—prostate cancer	2.12e-05	0.000111	CcSEcCtD
Sitaxentan—Nervousness—Epirubicin—prostate cancer	2.09e-05	0.000109	CcSEcCtD
Sitaxentan—Feeling abnormal—Capecitabine—prostate cancer	2.08e-05	0.000109	CcSEcCtD
Sitaxentan—Angiopathy—Doxorubicin—prostate cancer	2.08e-05	0.000109	CcSEcCtD
Sitaxentan—Dizziness—Etoposide—prostate cancer	2.08e-05	0.000109	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—prostate cancer	2.07e-05	0.000108	CcSEcCtD
Sitaxentan—Immune system disorder—Doxorubicin—prostate cancer	2.07e-05	0.000108	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—prostate cancer	2.07e-05	0.000108	CcSEcCtD
Sitaxentan—Body temperature increased—Docetaxel—prostate cancer	2.06e-05	0.000108	CcSEcCtD
Sitaxentan—Insomnia—Prednisone—prostate cancer	2.03e-05	0.000106	CcSEcCtD
Sitaxentan—Alopecia—Doxorubicin—prostate cancer	2.02e-05	0.000106	CcSEcCtD
Sitaxentan—Mental disorder—Doxorubicin—prostate cancer	2.01e-05	0.000105	CcSEcCtD
Sitaxentan—Urticaria—Capecitabine—prostate cancer	2.01e-05	0.000105	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—prostate cancer	2e-05	0.000105	CcSEcCtD
Sitaxentan—Body temperature increased—Capecitabine—prostate cancer	2e-05	0.000104	CcSEcCtD
Sitaxentan—Vomiting—Etoposide—prostate cancer	2e-05	0.000104	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—prostate cancer	1.99e-05	0.000104	CcSEcCtD
Sitaxentan—Anaemia—Epirubicin—prostate cancer	1.99e-05	0.000104	CcSEcCtD
Sitaxentan—Agitation—Epirubicin—prostate cancer	1.98e-05	0.000104	CcSEcCtD
Sitaxentan—Dyspepsia—Prednisone—prostate cancer	1.98e-05	0.000104	CcSEcCtD
Sitaxentan—Rash—Etoposide—prostate cancer	1.98e-05	0.000103	CcSEcCtD
Sitaxentan—Dermatitis—Etoposide—prostate cancer	1.98e-05	0.000103	CcSEcCtD
Sitaxentan—Headache—Etoposide—prostate cancer	1.97e-05	0.000103	CcSEcCtD
Sitaxentan—Tension—Doxorubicin—prostate cancer	1.96e-05	0.000102	CcSEcCtD
Sitaxentan—Decreased appetite—Prednisone—prostate cancer	1.96e-05	0.000102	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—prostate cancer	1.94e-05	0.000102	CcSEcCtD
Sitaxentan—Fatigue—Prednisone—prostate cancer	1.94e-05	0.000101	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—prostate cancer	1.94e-05	0.000101	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—prostate cancer	1.94e-05	0.000101	CcSEcCtD
Sitaxentan—Leukopenia—Epirubicin—prostate cancer	1.93e-05	0.000101	CcSEcCtD
Sitaxentan—Constipation—Prednisone—prostate cancer	1.92e-05	0.000101	CcSEcCtD
Sitaxentan—Hypersensitivity—Docetaxel—prostate cancer	1.92e-05	0.0001	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—prostate cancer	1.92e-05	0.0001	CcSEcCtD
Sitaxentan—Asthenia—Docetaxel—prostate cancer	1.87e-05	9.79e-05	CcSEcCtD
Sitaxentan—Nausea—Etoposide—prostate cancer	1.86e-05	9.75e-05	CcSEcCtD
Sitaxentan—Hypersensitivity—Capecitabine—prostate cancer	1.86e-05	9.73e-05	CcSEcCtD
Sitaxentan—Feeling abnormal—Prednisone—prostate cancer	1.85e-05	9.69e-05	CcSEcCtD
Sitaxentan—Ill-defined disorder—Doxorubicin—prostate cancer	1.85e-05	9.68e-05	CcSEcCtD
Sitaxentan—Anaemia—Doxorubicin—prostate cancer	1.84e-05	9.64e-05	CcSEcCtD
Sitaxentan—Chest pain—Epirubicin—prostate cancer	1.84e-05	9.6e-05	CcSEcCtD
Sitaxentan—Agitation—Doxorubicin—prostate cancer	1.83e-05	9.59e-05	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.82e-05	9.53e-05	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—prostate cancer	1.81e-05	9.48e-05	CcSEcCtD
Sitaxentan—Asthenia—Capecitabine—prostate cancer	1.81e-05	9.48e-05	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—prostate cancer	1.8e-05	9.41e-05	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—prostate cancer	1.79e-05	9.39e-05	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—prostate cancer	1.79e-05	9.37e-05	CcSEcCtD
Sitaxentan—Urticaria—Prednisone—prostate cancer	1.79e-05	9.35e-05	CcSEcCtD
Sitaxentan—Leukopenia—Doxorubicin—prostate cancer	1.79e-05	9.34e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Docetaxel—prostate cancer	1.78e-05	9.33e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Prednisone—prostate cancer	1.78e-05	9.3e-05	CcSEcCtD
Sitaxentan—Confusional state—Epirubicin—prostate cancer	1.77e-05	9.28e-05	CcSEcCtD
Sitaxentan—Oedema—Epirubicin—prostate cancer	1.76e-05	9.2e-05	CcSEcCtD
Sitaxentan—Infection—Epirubicin—prostate cancer	1.75e-05	9.14e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Capecitabine—prostate cancer	1.73e-05	9.04e-05	CcSEcCtD
Sitaxentan—Nervous system disorder—Epirubicin—prostate cancer	1.73e-05	9.02e-05	CcSEcCtD
Sitaxentan—Dizziness—Docetaxel—prostate cancer	1.72e-05	9.02e-05	CcSEcCtD
Sitaxentan—Thrombocytopenia—Epirubicin—prostate cancer	1.72e-05	9.01e-05	CcSEcCtD
Sitaxentan—Tachycardia—Epirubicin—prostate cancer	1.72e-05	8.98e-05	CcSEcCtD
Sitaxentan—Skin disorder—Epirubicin—prostate cancer	1.71e-05	8.94e-05	CcSEcCtD
Sitaxentan—Chest pain—Doxorubicin—prostate cancer	1.7e-05	8.88e-05	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.69e-05	8.82e-05	CcSEcCtD
Sitaxentan—Discomfort—Doxorubicin—prostate cancer	1.68e-05	8.77e-05	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—prostate cancer	1.68e-05	8.77e-05	CcSEcCtD
Sitaxentan—Dizziness—Capecitabine—prostate cancer	1.67e-05	8.73e-05	CcSEcCtD
Sitaxentan—Dry mouth—Doxorubicin—prostate cancer	1.66e-05	8.68e-05	CcSEcCtD
Sitaxentan—Vomiting—Docetaxel—prostate cancer	1.66e-05	8.67e-05	CcSEcCtD
Sitaxentan—Hypersensitivity—Prednisone—prostate cancer	1.66e-05	8.67e-05	CcSEcCtD
Sitaxentan—Rash—Docetaxel—prostate cancer	1.64e-05	8.6e-05	CcSEcCtD
Sitaxentan—Hypotension—Epirubicin—prostate cancer	1.64e-05	8.6e-05	CcSEcCtD
Sitaxentan—Dermatitis—Docetaxel—prostate cancer	1.64e-05	8.59e-05	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—prostate cancer	1.64e-05	8.58e-05	CcSEcCtD
Sitaxentan—Headache—Docetaxel—prostate cancer	1.63e-05	8.55e-05	CcSEcCtD
Sitaxentan—Oedema—Doxorubicin—prostate cancer	1.63e-05	8.51e-05	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—prostate cancer	1.62e-05	8.46e-05	CcSEcCtD
Sitaxentan—Asthenia—Prednisone—prostate cancer	1.61e-05	8.44e-05	CcSEcCtD
Sitaxentan—Vomiting—Capecitabine—prostate cancer	1.61e-05	8.4e-05	CcSEcCtD
Sitaxentan—Nervous system disorder—Doxorubicin—prostate cancer	1.6e-05	8.35e-05	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—prostate cancer	1.59e-05	8.34e-05	CcSEcCtD
Sitaxentan—Rash—Capecitabine—prostate cancer	1.59e-05	8.33e-05	CcSEcCtD
Sitaxentan—Insomnia—Epirubicin—prostate cancer	1.59e-05	8.32e-05	CcSEcCtD
Sitaxentan—Dermatitis—Capecitabine—prostate cancer	1.59e-05	8.32e-05	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—prostate cancer	1.59e-05	8.31e-05	CcSEcCtD
Sitaxentan—Headache—Capecitabine—prostate cancer	1.58e-05	8.27e-05	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—prostate cancer	1.58e-05	8.27e-05	CcSEcCtD
Sitaxentan—Somnolence—Epirubicin—prostate cancer	1.56e-05	8.18e-05	CcSEcCtD
Sitaxentan—Anorexia—Doxorubicin—prostate cancer	1.55e-05	8.11e-05	CcSEcCtD
Sitaxentan—Nausea—Docetaxel—prostate cancer	1.55e-05	8.1e-05	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—prostate cancer	1.55e-05	8.1e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Prednisone—prostate cancer	1.54e-05	8.05e-05	CcSEcCtD
Sitaxentan—Decreased appetite—Epirubicin—prostate cancer	1.53e-05	8e-05	CcSEcCtD
Sitaxentan—Hypotension—Doxorubicin—prostate cancer	1.52e-05	7.95e-05	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—prostate cancer	1.52e-05	7.94e-05	CcSEcCtD
Sitaxentan—Fatigue—Epirubicin—prostate cancer	1.52e-05	7.93e-05	CcSEcCtD
Sitaxentan—Pain—Epirubicin—prostate cancer	1.5e-05	7.87e-05	CcSEcCtD
Sitaxentan—Constipation—Epirubicin—prostate cancer	1.5e-05	7.87e-05	CcSEcCtD
Sitaxentan—Nausea—Capecitabine—prostate cancer	1.5e-05	7.84e-05	CcSEcCtD
Sitaxentan—Dizziness—Prednisone—prostate cancer	1.49e-05	7.78e-05	CcSEcCtD
Sitaxentan—Insomnia—Doxorubicin—prostate cancer	1.47e-05	7.7e-05	CcSEcCtD
Sitaxentan—Feeling abnormal—Epirubicin—prostate cancer	1.45e-05	7.58e-05	CcSEcCtD
Sitaxentan—Somnolence—Doxorubicin—prostate cancer	1.45e-05	7.57e-05	CcSEcCtD
Sitaxentan—Dyspepsia—Doxorubicin—prostate cancer	1.43e-05	7.49e-05	CcSEcCtD
Sitaxentan—Vomiting—Prednisone—prostate cancer	1.43e-05	7.48e-05	CcSEcCtD
Sitaxentan—Rash—Prednisone—prostate cancer	1.42e-05	7.42e-05	CcSEcCtD
Sitaxentan—Dermatitis—Prednisone—prostate cancer	1.42e-05	7.41e-05	CcSEcCtD
Sitaxentan—Decreased appetite—Doxorubicin—prostate cancer	1.42e-05	7.4e-05	CcSEcCtD
Sitaxentan—Headache—Prednisone—prostate cancer	1.41e-05	7.37e-05	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.41e-05	7.35e-05	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—prostate cancer	1.4e-05	7.34e-05	CcSEcCtD
Sitaxentan—Urticaria—Epirubicin—prostate cancer	1.4e-05	7.31e-05	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—prostate cancer	1.39e-05	7.28e-05	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—prostate cancer	1.39e-05	7.28e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—prostate cancer	1.39e-05	7.27e-05	CcSEcCtD
Sitaxentan—Feeling abnormal—Doxorubicin—prostate cancer	1.34e-05	7.02e-05	CcSEcCtD
Sitaxentan—Nausea—Prednisone—prostate cancer	1.34e-05	6.99e-05	CcSEcCtD
Sitaxentan—Hypersensitivity—Epirubicin—prostate cancer	1.3e-05	6.78e-05	CcSEcCtD
Sitaxentan—Urticaria—Doxorubicin—prostate cancer	1.29e-05	6.76e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—prostate cancer	1.29e-05	6.73e-05	CcSEcCtD
Sitaxentan—Asthenia—Epirubicin—prostate cancer	1.26e-05	6.6e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Epirubicin—prostate cancer	1.2e-05	6.3e-05	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—prostate cancer	1.2e-05	6.27e-05	CcSEcCtD
Sitaxentan—Asthenia—Doxorubicin—prostate cancer	1.17e-05	6.11e-05	CcSEcCtD
Sitaxentan—Dizziness—Epirubicin—prostate cancer	1.16e-05	6.08e-05	CcSEcCtD
Sitaxentan—Vomiting—Epirubicin—prostate cancer	1.12e-05	5.85e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—prostate cancer	1.11e-05	5.82e-05	CcSEcCtD
Sitaxentan—Rash—Epirubicin—prostate cancer	1.11e-05	5.8e-05	CcSEcCtD
Sitaxentan—Dermatitis—Epirubicin—prostate cancer	1.11e-05	5.8e-05	CcSEcCtD
Sitaxentan—Headache—Epirubicin—prostate cancer	1.1e-05	5.76e-05	CcSEcCtD
Sitaxentan—Dizziness—Doxorubicin—prostate cancer	1.08e-05	5.63e-05	CcSEcCtD
Sitaxentan—Nausea—Epirubicin—prostate cancer	1.05e-05	5.46e-05	CcSEcCtD
Sitaxentan—Vomiting—Doxorubicin—prostate cancer	1.04e-05	5.41e-05	CcSEcCtD
Sitaxentan—Rash—Doxorubicin—prostate cancer	1.03e-05	5.37e-05	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—prostate cancer	1.03e-05	5.36e-05	CcSEcCtD
Sitaxentan—Headache—Doxorubicin—prostate cancer	1.02e-05	5.33e-05	CcSEcCtD
Sitaxentan—Nausea—Doxorubicin—prostate cancer	9.67e-06	5.06e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—prostate cancer	7.15e-06	7.65e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MDM2—prostate cancer	7.12e-06	7.62e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC22A3—prostate cancer	7.11e-06	7.61e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HSD3B1—prostate cancer	7.11e-06	7.61e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTA1—prostate cancer	7.03e-06	7.53e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB2—prostate cancer	7.02e-06	7.51e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NAT2—prostate cancer	6.95e-06	7.44e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HSD3B2—prostate cancer	6.95e-06	7.44e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTO1—prostate cancer	6.95e-06	7.44e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—prostate cancer	6.95e-06	7.44e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFB1—prostate cancer	6.93e-06	7.42e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CB—prostate cancer	6.93e-06	7.41e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	6.9e-06	7.39e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TBXAS1—prostate cancer	6.82e-06	7.3e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTA4—prostate cancer	6.82e-06	7.3e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—prostate cancer	6.8e-06	7.27e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	6.69e-06	7.16e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—LRP2—prostate cancer	6.67e-06	7.14e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PLCB2—prostate cancer	6.67e-06	7.14e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP2C18—prostate cancer	6.67e-06	7.14e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	6.67e-06	7.13e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—prostate cancer	6.66e-06	7.12e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTA2—prostate cancer	6.65e-06	7.11e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SULT1A1—prostate cancer	6.57e-06	7.03e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCG5—prostate cancer	6.57e-06	7.03e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—P4HB—prostate cancer	6.54e-06	7e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1B—prostate cancer	6.5e-06	6.96e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HPGD—prostate cancer	6.49e-06	6.95e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—B4GALT4—prostate cancer	6.49e-06	6.95e-05	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—prostate cancer	6.43e-06	6.88e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—prostate cancer	6.42e-06	6.87e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTA1—prostate cancer	6.41e-06	6.86e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CASP3—prostate cancer	6.37e-06	6.82e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC22A1—prostate cancer	6.36e-06	6.81e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—prostate cancer	6.36e-06	6.81e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HSD3B2—prostate cancer	6.34e-06	6.79e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTO1—prostate cancer	6.34e-06	6.79e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NAT2—prostate cancer	6.34e-06	6.79e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—prostate cancer	6.33e-06	6.77e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	6.29e-06	6.73e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—prostate cancer	6.2e-06	6.64e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SULT2A1—prostate cancer	6.2e-06	6.63e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CTNNB1—prostate cancer	6.14e-06	6.57e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TNFRSF21—prostate cancer	6.1e-06	6.53e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MED12—prostate cancer	6.1e-06	6.53e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	6.1e-06	6.53e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PLCB2—prostate cancer	6.08e-06	6.51e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—LRP2—prostate cancer	6.08e-06	6.51e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP2C18—prostate cancer	6.08e-06	6.51e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNG5—prostate cancer	6.05e-06	6.47e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—prostate cancer	6.02e-06	6.44e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1A—prostate cancer	6e-06	6.42e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—prostate cancer	5.98e-06	6.4e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—P4HB—prostate cancer	5.96e-06	6.38e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTAP—prostate cancer	5.94e-06	6.35e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP7B1—prostate cancer	5.94e-06	6.35e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—prostate cancer	5.9e-06	6.31e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—prostate cancer	5.84e-06	6.25e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NCOA3—prostate cancer	5.83e-06	6.24e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC22A1—prostate cancer	5.8e-06	6.21e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SULT1E1—prostate cancer	5.78e-06	6.19e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SRD5A1—prostate cancer	5.78e-06	6.19e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	5.73e-06	6.14e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	5.73e-06	6.13e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EP300—prostate cancer	5.71e-06	6.11e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—prostate cancer	5.71e-06	6.11e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SULT2A1—prostate cancer	5.65e-06	6.05e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MED12—prostate cancer	5.56e-06	5.95e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HPGDS—prostate cancer	5.56e-06	5.95e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SRC—prostate cancer	5.55e-06	5.94e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HSD17B3—prostate cancer	5.52e-06	5.91e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ACSL4—prostate cancer	5.52e-06	5.91e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNG5—prostate cancer	5.52e-06	5.9e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—prostate cancer	5.41e-06	5.78e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ACHE—prostate cancer	5.39e-06	5.77e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTT1—prostate cancer	5.39e-06	5.77e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—prostate cancer	5.35e-06	5.73e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP2A6—prostate cancer	5.33e-06	5.7e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NCOA3—prostate cancer	5.31e-06	5.69e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	5.31e-06	5.68e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PHGDH—prostate cancer	5.29e-06	5.66e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—UMPS—prostate cancer	5.29e-06	5.66e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ARG2—prostate cancer	5.29e-06	5.66e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—prostate cancer	5.22e-06	5.59e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	5.22e-06	5.59e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—LDHB—prostate cancer	5.19e-06	5.55e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKR1C3—prostate cancer	5.19e-06	5.55e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PRKACB—prostate cancer	5.16e-06	5.52e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP17A1—prostate cancer	5.1e-06	5.46e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP3A5—prostate cancer	5.09e-06	5.45e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HPGDS—prostate cancer	5.07e-06	5.43e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP2C19—prostate cancer	5.04e-06	5.39e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.03e-06	5.39e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—prostate cancer	4.97e-06	5.32e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFB1—prostate cancer	4.96e-06	5.31e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PDHA1—prostate cancer	4.92e-06	5.26e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TCN2—prostate cancer	4.92e-06	5.26e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTA3—prostate cancer	4.92e-06	5.26e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—UCP3—prostate cancer	4.92e-06	5.26e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTT1—prostate cancer	4.92e-06	5.26e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ACHE—prostate cancer	4.92e-06	5.26e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—prostate cancer	4.86e-06	5.21e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NCOA2—prostate cancer	4.86e-06	5.21e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP2A6—prostate cancer	4.86e-06	5.2e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.84e-06	5.18e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—prostate cancer	4.82e-06	5.16e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKR1C3—prostate cancer	4.73e-06	5.06e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PRKACB—prostate cancer	4.7e-06	5.03e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HSD3B1—prostate cancer	4.69e-06	5.02e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC22A3—prostate cancer	4.69e-06	5.02e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP17A1—prostate cancer	4.65e-06	4.98e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC5A5—prostate cancer	4.64e-06	4.97e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—prostate cancer	4.6e-06	4.92e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.59e-06	4.91e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP2E1—prostate cancer	4.53e-06	4.85e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTA4—prostate cancer	4.5e-06	4.81e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TBXAS1—prostate cancer	4.5e-06	4.81e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NQO1—prostate cancer	4.48e-06	4.8e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NCOA2—prostate cancer	4.44e-06	4.75e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TH—prostate cancer	4.42e-06	4.73e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.39e-06	4.7e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTA2—prostate cancer	4.38e-06	4.69e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP3A4—prostate cancer	4.37e-06	4.68e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.35e-06	4.65e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCG5—prostate cancer	4.33e-06	4.63e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SULT1A1—prostate cancer	4.33e-06	4.63e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1B1—prostate cancer	4.3e-06	4.6e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC5A5—prostate cancer	4.23e-06	4.53e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTA1—prostate cancer	4.23e-06	4.53e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—prostate cancer	4.22e-06	4.52e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTO1—prostate cancer	4.18e-06	4.48e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NAT2—prostate cancer	4.18e-06	4.48e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HSD3B2—prostate cancer	4.18e-06	4.48e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GGT1—prostate cancer	4.16e-06	4.45e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP2E1—prostate cancer	4.13e-06	4.42e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NCOA1—prostate cancer	4.1e-06	4.39e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NQO1—prostate cancer	4.09e-06	4.37e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—prostate cancer	4.08e-06	4.37e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP19A1—prostate cancer	4.04e-06	4.32e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TH—prostate cancer	4.03e-06	4.31e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—LRP2—prostate cancer	4.01e-06	4.29e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.01e-06	4.29e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PLCB2—prostate cancer	4.01e-06	4.29e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4e-06	4.28e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP3A4—prostate cancer	3.98e-06	4.26e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.96e-06	4.24e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—P4HB—prostate cancer	3.93e-06	4.21e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1B1—prostate cancer	3.92e-06	4.19e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—RXRA—prostate cancer	3.9e-06	4.17e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.82e-06	4.09e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GGT1—prostate cancer	3.79e-06	4.06e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.79e-06	4.06e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—COMT—prostate cancer	3.76e-06	4.02e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—prostate cancer	3.74e-06	4e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTP1—prostate cancer	3.74e-06	4e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NCOA1—prostate cancer	3.74e-06	4e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.73e-06	3.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP19A1—prostate cancer	3.68e-06	3.94e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ITPR1—prostate cancer	3.68e-06	3.94e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MED12—prostate cancer	3.67e-06	3.92e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNG5—prostate cancer	3.64e-06	3.89e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.62e-06	3.87e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—RXRA—prostate cancer	3.55e-06	3.8e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NCOA3—prostate cancer	3.5e-06	3.75e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TYMS—prostate cancer	3.47e-06	3.72e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.46e-06	3.7e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—prostate cancer	3.45e-06	3.69e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTM1—prostate cancer	3.43e-06	3.68e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—COMT—prostate cancer	3.42e-06	3.66e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTP1—prostate cancer	3.41e-06	3.65e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—LPL—prostate cancer	3.37e-06	3.61e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ITPR1—prostate cancer	3.35e-06	3.59e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HPGDS—prostate cancer	3.34e-06	3.58e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.32e-06	3.56e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.3e-06	3.53e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1A1—prostate cancer	3.26e-06	3.48e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ACHE—prostate cancer	3.24e-06	3.47e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTT1—prostate cancer	3.24e-06	3.47e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ERCC2—prostate cancer	3.23e-06	3.46e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.21e-06	3.43e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TYMS—prostate cancer	3.17e-06	3.39e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTM1—prostate cancer	3.13e-06	3.35e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.12e-06	3.34e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PRKACB—prostate cancer	3.1e-06	3.32e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—LPL—prostate cancer	3.07e-06	3.29e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.07e-06	3.29e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTHFR—prostate cancer	3.04e-06	3.25e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARA—prostate cancer	2.98e-06	3.19e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.97e-06	3.18e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ERCC2—prostate cancer	2.94e-06	3.15e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NCOA2—prostate cancer	2.92e-06	3.13e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CAV1—prostate cancer	2.8e-06	3e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.79e-06	2.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTHFR—prostate cancer	2.77e-06	2.96e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.73e-06	2.92e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARA—prostate cancer	2.72e-06	2.91e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NQO1—prostate cancer	2.69e-06	2.88e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.68e-06	2.86e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TH—prostate cancer	2.66e-06	2.84e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.58e-06	2.77e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CAV1—prostate cancer	2.55e-06	2.73e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.55e-06	2.73e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GGT1—prostate cancer	2.5e-06	2.68e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NCOA1—prostate cancer	2.46e-06	2.64e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.44e-06	2.61e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.43e-06	2.6e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—INS—prostate cancer	2.41e-06	2.58e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CREBBP—prostate cancer	2.36e-06	2.53e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—RXRA—prostate cancer	2.34e-06	2.51e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.33e-06	2.49e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—COMT—prostate cancer	2.26e-06	2.42e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTP1—prostate cancer	2.25e-06	2.41e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.24e-06	2.4e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ITPR1—prostate cancer	2.21e-06	2.37e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—INS—prostate cancer	2.2e-06	2.36e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CREBBP—prostate cancer	2.16e-06	2.31e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NOS3—prostate cancer	2.12e-06	2.27e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TYMS—prostate cancer	2.09e-06	2.24e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTM1—prostate cancer	2.07e-06	2.21e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.04e-06	2.19e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—LPL—prostate cancer	2.03e-06	2.17e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.96e-06	2.1e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.95e-06	2.09e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ERCC2—prostate cancer	1.94e-06	2.08e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—prostate cancer	1.94e-06	2.07e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NOS3—prostate cancer	1.93e-06	2.07e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTHFR—prostate cancer	1.83e-06	1.95e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARA—prostate cancer	1.79e-06	1.92e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.78e-06	1.91e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—prostate cancer	1.77e-06	1.89e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—prostate cancer	1.69e-06	1.81e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CAV1—prostate cancer	1.68e-06	1.8e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—EP300—prostate cancer	1.61e-06	1.72e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—prostate cancer	1.54e-06	1.65e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.53e-06	1.64e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—EP300—prostate cancer	1.47e-06	1.57e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—INS—prostate cancer	1.45e-06	1.55e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CREBBP—prostate cancer	1.42e-06	1.52e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.35e-06	1.44e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NOS3—prostate cancer	1.27e-06	1.36e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.19e-06	1.27e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.18e-06	1.26e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—prostate cancer	1.16e-06	1.25e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.09e-06	1.16e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—prostate cancer	1.02e-06	1.09e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—prostate cancer	9.73e-07	1.04e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—EP300—prostate cancer	9.68e-07	1.04e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—prostate cancer	8.87e-07	9.5e-06	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—prostate cancer	7.16e-07	7.67e-06	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—prostate cancer	5.85e-07	6.26e-06	CbGpPWpGaD
